Development
J&J's Talvey plus Darzalex combo hits PFS endpoint in Phase III multiple myeloma trial
Phase III data from the MonumenTAL-3 trial, reported by Johnson & Johnson (NYSE: JNJ) at the 2026 European Hematology Association Annual Meeting,...
Traws faces regulatory setbacks for tivoxavir marboxil in influenza challenge trial
A negative regulatory review from the UK's Medicines and Healthcare Products Regulatory Agency has effectively halted the most advanced clinical milestone...
Gan & Lee's posts competitive Phase III readouts for bi-weekly GLP-1 contender bofanglutide, basal insulin ludefen
China-based Gan & Lee Pharmaceuticals (603087.SH) reported simultaneous positive Phase III readouts for two metabolic disease candidates on June 12,...
Novartis displays Rhapsido's Phase III efficacy across chronic urticaria subtypes at EAACI
Remibrutinib (Rhapsido) has become the first therapy to demonstrate statistically significant efficacy across all three major subtypes of chronic inducible...
Jazz faces uncertainty over Zepzelca's accelerated approval after Phase III LAGOON failure
The Phase III LAGOON trial has failed to confirm the second-line benefit of lurbinectedin (Zepzelca) in relapsed small cell lung cancer, a result that puts...
Novartis's FAP-targeting radioligand enters Phase I for solid tumors
Novartis has initiated a first-in-human Phase I trial of [⁶⁸Ga]Ga-DFC413 (JFI447), a Gallium-68-labeled radioligand designed to image fibroblast activation...
PeptiDream's CLDN18.2 radiopharmaceutical enters first-in-human study in gastric cancer
Japan-based PeptiDream Inc. (Tokyo Stock Exchange: 4587) has announced the first patient dosing in a first-in-human radiopharmaceutical clinical trial of...
Adlai Nortye's PD-L1, CD86, and LAG-3 tri-specific fusion protein enters Phase I testing
Nasdaq-listed Adlai Nortye Biopharma Co., Ltd. (Nasdaq: ANL) has initiated a first-in-human clinical trial of AN8025, a tri-specific antibody fusion protein...
Immunome's debuts first-in-class ADC targeting mystery immune-excluding receptor tyrosine kinase
Bothell, Washington-based Immunome, Inc. (Nasdaq: IMNM) has dosed the first patient in a Phase I first-in-human study of IM-1617, an antibody-drug conjugate...
Takeda's zasocitinib outperforms BMS's Sotyktu in Phase III plaque psoriasis trial
Takeda (TSE:4502/NYSE:TAK) has reported that zasocitinib demonstrated statistically significant superiority over Bristol Myers Squibb's Sotyktu...
Novartis's Avidity-acquired AOC del-brax meets primary endpoint in Phase I/II FSHD trial
Novartis (SWX: NOVN.SW) reported that delpacibart braxlosiran (del-brax), its investigational antibody oligonucleotide conjugate (AOC) for...
N-Zyme repurposing HIV drug fosamprenavir for laryngopharyngeal reflux disease
N-Zyme Biomedical, a clinical-stage company headquartered in Delaware, announced the initiation of a Phase II trial of fosamprenavir for laryngopharyngeal...
TG Therapeutics aiming to expand Briumvi to myasthenia gravis after positive early data
TG Therapeutics (Nasdaq: TGTX) reported Phase I data showing that subcutaneous ublituximab (Briumvi), its glycoengineered anti-CD20 B-cell depleting...
Sanofi cuts off riliprubart's Phase III in CIDP after lack of efficacy
Sanofi (Euronext: SAN; Nasdaq: SNY) announced the termination of its MOBILIZE Phase III trial of riliprubart (SAR445088, BIVV020) in CIDP patients...
ADA: Lilly's Foundayo outperforms Ozempic and Farxiga in three Phase III type 2 diabetes trials
Eli Lilly and Company (NYSE: LLY) reported Phase III data from three ACHIEVE program trials showing that orforglipron (Foundayo), its once-daily oral GLP-1...
The AllSci Brief
Systematic R&D and deal news. Daily.